Abstract
Leiomyosarcoma of the urinary bladder is a rare mesenchymal tumor with distinct pathologic features. Although radical cystectomy is the standard therapy for locally invasive disease, available literature appears to support the benefit of perioperative chemotherapy, similar to that seen with the more conventional urothelial malignancies. We report on a 77-year-old gentleman with locally advanced leiomyosarcoma of the bladder achieving a near-complete pathologic response to neoadjuvant chemotherapy with a unique regimen: gemcitabine and docetaxel. Further study of this anthracycline-sparing regimen is warranted.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Disease-Free Survival
-
Docetaxel
-
Gemcitabine
-
Humans
-
Leiomyosarcoma* / drug therapy
-
Leiomyosarcoma* / pathology
-
Male
-
Neoadjuvant Therapy
-
Neoplasm Invasiveness
-
Taxoids / administration & dosage
-
Taxoids / adverse effects
-
Taxoids / therapeutic use
-
Urinary Bladder Neoplasms* / drug therapy
-
Urinary Bladder Neoplasms* / pathology
Substances
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Gemcitabine